发明名称 ANWENDUNG EINES DIALYSATS MIT HOHEM ZITRATGEHALT
摘要 <p>The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-diaysis serum HCO 3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-diaysis serum HCO 3 >23mEq/L (lower limit or normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO 3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.19 to 1.34±0.2 (p=0.01). This increased urea clearance may be the result of the anticoagulant property of citrate maintaining patency of the dialyzer membrane. The increase in pre-dialysis serum HCO 3 may represent increased delivery from the dialysate and production from citric acid.</p>
申请公布号 AT422915(T) 申请公布日期 2009.03.15
申请号 AT20000965346T 申请日期 2000.09.22
申请人 ADVANCED RENAL TECHNOLOGIES 发明人 CALLAN, ROBIN;JAMES J.COLE
分类号 A61M1/16;A61K31/19;A61K31/191;A61K33/10;A61K33/14;A61M1/36 主分类号 A61M1/16
代理机构 代理人
主权项
地址